HRP20030426A2 - Use of sarp-1 for the treatment and/or preventionof scleroderma - Google Patents

Use of sarp-1 for the treatment and/or preventionof scleroderma Download PDF

Info

Publication number
HRP20030426A2
HRP20030426A2 HR20030426A HRP20030426A HRP20030426A2 HR P20030426 A2 HRP20030426 A2 HR P20030426A2 HR 20030426 A HR20030426 A HR 20030426A HR P20030426 A HRP20030426 A HR P20030426A HR P20030426 A2 HRP20030426 A2 HR P20030426A2
Authority
HR
Croatia
Prior art keywords
sarp
scleroderma
polypeptide
seq
identification
Prior art date
Application number
HR20030426A
Other languages
English (en)
Croatian (hr)
Inventor
Plater-Zyberk Christine
Power Christine
Colinge Jacques
Original Assignee
Applied Research Systems Ars Holding N.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Applied Research Systems Ars Holding N.V. filed Critical Applied Research Systems Ars Holding N.V.
Publication of HRP20030426A2 publication Critical patent/HRP20030426A2/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
HR20030426A 2000-12-06 2001-11-30 Use of sarp-1 for the treatment and/or preventionof scleroderma HRP20030426A2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP00126771 2000-12-06
EP01118888 2001-08-17
PCT/EP2001/013992 WO2002046225A2 (en) 2000-12-06 2001-11-30 Use of sarp-1 for the treatment and/or prevention of scleroderma

Publications (1)

Publication Number Publication Date
HRP20030426A2 true HRP20030426A2 (en) 2005-04-30

Family

ID=26071647

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20030426A HRP20030426A2 (en) 2000-12-06 2001-11-30 Use of sarp-1 for the treatment and/or preventionof scleroderma

Country Status (29)

Country Link
US (2) US7341995B2 (cs)
EP (2) EP1411970B1 (cs)
JP (1) JP2004525869A (cs)
KR (1) KR100804885B1 (cs)
CN (1) CN1323716C (cs)
AT (1) ATE359808T1 (cs)
AU (2) AU2002226366B2 (cs)
BG (1) BG107941A (cs)
BR (1) BR0115983A (cs)
CA (1) CA2428092A1 (cs)
CY (1) CY1107687T1 (cs)
CZ (1) CZ20031855A3 (cs)
DE (1) DE60128009T2 (cs)
DK (1) DK1411970T3 (cs)
EA (1) EA005973B1 (cs)
EE (1) EE200300213A (cs)
ES (1) ES2281463T3 (cs)
HR (1) HRP20030426A2 (cs)
HU (1) HUP0302738A3 (cs)
IL (1) IL156069A0 (cs)
MX (1) MXPA03005027A (cs)
NO (1) NO20032597L (cs)
NZ (1) NZ525774A (cs)
PL (1) PL365316A1 (cs)
PT (1) PT1411970E (cs)
SK (1) SK8472003A3 (cs)
UA (1) UA83790C2 (cs)
WO (1) WO2002046225A2 (cs)
YU (1) YU45103A (cs)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4899397A (en) * 1997-02-06 1998-08-26 Genetics Institute, Llc Human sdf-5 protein and compositions
HRP20040877A2 (en) * 2002-04-10 2005-02-28 Applied Research Systems Ars Holding N.V. Use of osteoprotegerin for the treatment and/or prevention of fibrotic disease
US7585840B2 (en) 2002-04-10 2009-09-08 Merck Serono S.A. Use of osteoprotegerin for the treatment and/or prevention of fibrotic disease
US9046537B2 (en) * 2003-09-22 2015-06-02 Enzo Biochem, Inc. Method for treating inflammation by administering a compound which binds LDL-receptor-related protein (LRP) ligand binding domain
SE0400489D0 (sv) * 2004-02-27 2004-02-27 Biovitrum Ab Therapeutic proteins
PT1850873T (pt) 2005-02-08 2019-02-19 Genzyme Corp Anticorpos contra tgfbeta
JP5025646B2 (ja) * 2005-11-08 2012-09-12 公益財団法人先端医療振興財団 虚血性心疾患の治療方法
WO2009074637A1 (en) * 2007-12-13 2009-06-18 Merck Serono S.A. Sarp-1 fusion proteins and uses thereof
HUE027481T2 (en) * 2011-03-11 2016-09-28 Celgene Corp Methods of treating cancer using 3-(5-amino-2-methyl-4-oxo-4h-quinazolin-3-yl)-piperidine-2,6-dione
WO2022217037A1 (en) 2021-04-09 2022-10-13 Board Of Regents, The University Of Texas System Compositions and methods for treatment of chronic lung diseases
CN117756910A (zh) * 2023-12-22 2024-03-26 首都医科大学附属北京口腔医院 Sfrp2功能多肽及其应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2855189A (en) * 1988-01-25 1989-07-27 Baker Cummins Dermatologicals, Inc. Method of treating fibrotic disorders
US5266575A (en) * 1991-11-06 1993-11-30 Minnesota Mining And Manufacturing Company 2-ethyl 1H-imidazo[4,5-ciquinolin-4-amines
US5747639A (en) * 1996-03-06 1998-05-05 Amgen Boulder Inc. Use of hydrophobic interaction chromatography to purify polyethylene glycols
TW555765B (en) * 1996-07-09 2003-10-01 Amgen Inc Low molecular weight soluble tumor necrosis factor type-I and type-II proteins
AU737323B2 (en) * 1996-09-24 2001-08-16 Genentech, Inc. A family of genes encoding apoptosis-related peptides, peptides encoded thereby and methods of use thereof
US5858715A (en) * 1997-01-29 1999-01-12 Incyte Pharmaceuticals, Inc. Human apoptosis-associated protein
AU4899397A (en) * 1997-02-06 1998-08-26 Genetics Institute, Llc Human sdf-5 protein and compositions
EP1121382B9 (en) * 1998-10-16 2007-07-04 Biogen Idec MA Inc. Interferon-beta fusion proteins and uses

Also Published As

Publication number Publication date
EP1806144A3 (en) 2008-04-23
BR0115983A (pt) 2003-12-30
UA83790C2 (ru) 2008-08-26
US20080107627A1 (en) 2008-05-08
DK1411970T3 (da) 2007-06-04
ES2281463T3 (es) 2007-10-01
HUP0302738A3 (en) 2010-01-28
NZ525774A (en) 2006-03-31
AU2002226366B2 (en) 2007-03-22
CN1323716C (zh) 2007-07-04
BG107941A (bg) 2004-01-30
EP1806144A2 (en) 2007-07-11
IL156069A0 (en) 2003-12-23
CY1107687T1 (el) 2012-05-23
US7655628B2 (en) 2010-02-02
DE60128009D1 (de) 2007-05-31
CA2428092A1 (en) 2002-06-13
PL365316A1 (en) 2004-12-27
DE60128009T2 (de) 2007-08-23
AU2636602A (en) 2002-06-18
NO20032597D0 (no) 2003-06-06
ATE359808T1 (de) 2007-05-15
US7341995B2 (en) 2008-03-11
CZ20031855A3 (cs) 2003-09-17
KR100804885B1 (ko) 2008-02-20
WO2002046225A3 (en) 2004-01-08
KR20030076585A (ko) 2003-09-26
EP1411970B1 (en) 2007-04-18
EE200300213A (et) 2003-08-15
WO2002046225A2 (en) 2002-06-13
EA200300639A1 (ru) 2003-12-25
EA005973B1 (ru) 2005-08-25
CN1553806A (zh) 2004-12-08
NO20032597L (no) 2003-06-06
HK1068106A1 (zh) 2005-04-22
JP2004525869A (ja) 2004-08-26
PT1411970E (pt) 2007-05-31
US20050113291A1 (en) 2005-05-26
EP1411970A2 (en) 2004-04-28
HUP0302738A2 (hu) 2003-11-28
SK8472003A3 (en) 2003-10-07
YU45103A (sh) 2006-08-17
MXPA03005027A (es) 2003-09-05

Similar Documents

Publication Publication Date Title
US7655628B2 (en) Method for treating liver cirrhosis or interstitial pulmonary fibrosis
EP2419121B1 (en) Peptides targeting tnf family receptors and antagonizing tnf action, compositions, methods and uses thereof
JP4430403B2 (ja) 線維化疾患の治療および／または予防のためのオステオプロテゲリンの使用
US9403891B2 (en) Methods and compositions for modulating TNF/TNFR signaling
AU2002226366A1 (en) Use of SARP-1 for the treatment and/or prevention of scleroderma
US7585840B2 (en) Use of osteoprotegerin for the treatment and/or prevention of fibrotic disease
ZA200303508B (en) Use of SARP-1 for the treatment and/or prevention of scleroderma.
IL165485A (en) Use of osteoprotegerin in the preparation of medicaments
WO2005049063A2 (en) Use of secreted protein products for preventing and treating pancreatic diseases and/or obesity and/or metabolic syndrome

Legal Events

Date Code Title Description
A1OB Publication of a patent application
ARAI Request for the grant of a patent on the basis of the submitted results of a substantive examination of a patent application
PPPP Transfer of rights

Owner name: LABORATOIRES SERONO SA, CH

ODRP Renewal fee for the maintenance of a patent

Payment date: 20081128

Year of fee payment: 8

OBST Application withdrawn